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ABSTRACT
Mof4 family associated protein 1 (MRFAP1) is a 14 kDa nuclear protein, which 
involves in maintaining normal histone modification levels by negatively regulating 
recruitment of the NuA4 (nucleosome acetyltransferase of H4) histone acetyltransferase 
complex to chromatin. MRFAP1 has been identified as one of the most up-regulated 
proteins after NEDD8 (neural precursor cell expressed developmentally down- 
regulated 8) inhibition in multiple human cell lines. However, the biological function of 
MRFAP1 and the E3 ligase that targets MRFAP1 for destruction remain mysterious. Here 
we show, by using an immunoprecipitation-based proteomics screen, that MRFAP1 is an 
interactor of the F-box protein FBXW8. MRFAP1 is degraded by means of the ubiquitin 
ligase Cul7/FBXW8 during mitotic anaphase-telophase transition and accumulated in 
mitotic metaphase. Overexpression of FBXW8 increased the polyubiquitination and 
decreased the stability of MRFAP1, whereas knockdown of FBXW8 prolonged the half-
life of MRFAP1. Moreover, forced expression of MRFAP1 in HeLa cells caused growth 
retardation and genomic instability, leading to severe mitotic cell death. Thus, Cul7/
FBXW8-mediated destruction of MRFAP1 is a regulatory component monitoring the 
anaphase-telophase transition and preventing genomic instability.
INTRODUCTION
The specific, rapid, and temporally controlled 
proteolysis of cellular regulators by the ubiquitin-
proteasome system (UPS) determined the unidirectional 
progression through the cell cycle [1]. The specificity of this 
system is mainly determined by E3 ubiquitin ligases [2]. 
The Cullin-Ring Ligases (CRL) are the well-studied RING 
E3 ubiquitin ligases, among which the Skp1-Cullin1-Fbox 
(SCF) complex has been extensively characterized. To date, 
the Cullin family contains eight mammalian proteins, Cul1, 
Cul2, Cul3, Cul4A, Cul4B, Cul5, Cul7 and Cul9 [3]. 
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The SCF complexes compose of the scaffold 
protein Cul1, the RING finger protein Rbx1 and the 
adaptor protein Skp1 to bridge variable F-box proteins 
that determine substrate recognition and recruitment 
to the SCF complexes [4]. The human genome encodes 
more than 70 F-box proteins that contain a homologous 
40-amino-acid F-box domain which can be further divided 
into three major classes: the FBXW family, the FBXL 
family, and the FBXO family [5]. Among these F-box 
proteins, FBXW8 is not only the receptor component of an 
SCF complex, but also the unique F-box protein known to 
interact with Cul7 [6]. Cul7 interacts directly with FBXW8 
and indirectly with Skp1 in an FBXW8-dependent manner 
[6]. Interestingly, Cul7 has higher affinity with FBXW8 
than Cul1, and the placental phenotypes of FBXW8-/- 
and Cul7-/- mice are similar, indicating that Cul7 forms 
a ubiquitin E3 ligase complex with FBXW8 to target 
substrates for destruction [7]. In agreement with that, Cul7/
FBXW8 ubiquitin ligase-mediated HPK1 (hematopoietic 
progenitor kinase-1) degradation played a critical role in 
cell proliferation and differentiation [8].
Mof4 family associated protein 1 (MRFAP1) is 
highly conserved and only presents in mammals, which 
is consistent with its specific role in the regulation of 
mortality factor 4 like 1 (MORF4L1) protein complexes. 
MRFAP1 maintains the normal histone modification 
levels by negatively regulating recruitment of the NuA4 
histone acetyltransferase complex to chromatin [9]. It 
also regulates the transcription factors activities of the 
MRG family (Mas-related genes) via competing with 
MRGBP for binding to MORF4L1, and plays a role 
in spermatogenesis, possibly by regulating the hyper-
acetylation of chromatin on histone H4 [10]. Recently, by 
quantitative proteomic analysis, MRFAP1 has been shown 
to be degraded by CRL via the ubiquitin-proteasome 
system [10, 11]. However, which CRL family member 
involved in this process remains unknown. 
In this study, by using an immunoprecipitation-
based proteomics screen, we identified that MRFAP1 was 
an interactor of FBXW8. MRFAP1 was a novel cell cycle-
regulated protein degraded by Cul7/FBXW8 ubiquitin 
ligase during mitotic anaphase-telophase transition and 
accumulated in mitotic metaphase. Failure to degrade 
MRFAP1 in HeLa cells caused growth retardation and 
genomic instability, leading to severe mitotic cell death.
RESULTS
Proteomics screen identified MRFAP1 as a 
potential binding partner of Cul7/FBXW8 E3 
ligase complex
To systematically identify the candidate substrates 
of Cul7/FBXW8, we performed an immunoprecipitation-
based proteomics screen in 293T cell stably expressing 
Flag-FBXW8. MLN4924, a potent and selective inhibitor 
of NEDD8-activating enzyme, which specifically disrupts 
CRLs-mediated protein turnover, was used to prevent the 
degradation of potential FBXW8 substrates and might 
enhance the protein-protein interactions with FBXW8. 
The cell lysate from Flag-control or Flag-FBXW8 293T 
cells with 4 hours MLN4924 treatment were subjected to 
immunoprecipitation with anti-Flag M2 resin to purify 
SCF-FBXW8 complexes. The whole IP procedure was 
monitored by running all separated cell lysate components 
on SDS-PAGE, followed by Coomassie Brilliant Blue 
staining (Figure 1A). The gel was continuously cut and 
subjected to LC−MS/MS analysis. The results indicate that 
Cul7 but not Cul1 was the highest score interacting protein 
of FBXW8 group (data not shown) as expected. Among 
a number of peptides from putative novel substrates, 
we recovered two unique peptides from MRFAP1 
(EDIASLTR and TQVEASEESALNHLQNPGDAAEGR) 
(Figure 1B). The affinity efficiency for Flag-FBXW8 was 
very high, as almost all exogenously expressed FBXW8 
was accumulated in the elution group (Figure 1A). 
Moreover, MRFAP1 was detected in the final elution of 
Flag-FBXW8 group and flow through of both groups 
(Figure 1A), suggesting that at least one part of endogenous 
MRFAP1 was specifically associated with FBXW8. 
MRFAP1 is co-localized and associated with 
FBXW8 
To determine the subcellular distribution of FBXW8, 
and further verify the spatio-temporal possibility that 
FBXW8 and MRFAP1 might interact with each other in 
mammalian cells in vivo, we utilized immunofluorescence 
microscopy on HeLa cells co-expression of Flag-FBXW8 
and GFP-MRFAP1. As shown in Figure 2A, FBXW8 was 
distributed throughout the cytoplasm and less expressed 
in the nucleus of interphase cells. However, most 
MRFAP1 was distributed in the nucleus. Nevertheless, 
in agreement with our biochemistry data, the overlapping 
between FBXW8 and MRFAP1 in the nucleus was clearly 
observed (Figure 2A). Moreover, the interaction between 
exogenous FBXW8 and MRFAP1 was also confirmed by 
immunoprecipitation with either GFP or Flag antibodies 
(Figure 2B). Taken together, these data suggested that 
MRFAP1 was associated with FBXW8.
FBXW8 regulates MRFAP1 ubiquitination and 
degradation
Given the specific interaction between FBXW8 and 
MRFAP1, we then asked whether FBXW8 regulates the 
stability of MRFAP1. We found that depletion of FBXW8 
by siRNAs consistently increased the basal expression 
level of endogenous MRFAP1 (Figure 3A). Furthermore, 
overexpression of FBXW8 caused the decrease of endogenous 
MRFAP1 in a dose-dependent manner, which was rescued 
by proteasome inhibitor MG132 (Figure 3B), indicating 
Oncotarget97180www.impactjournals.com/oncotarget
that FBXW8 regulated the expression of MRFAP1 at 
posttranscriptional level. Indeed, overexpression of FBXW8 
significantly promotes the ubiquitination of MRFAP1, 
suggesting FBXW8 targets MRFAP1 for proteasome-
mediated degradation (Figure 3C). Moreover, 293T cells were 
treated with cycloheximide (CHX) to block protein synthesis. 
We found that overexpression of FBXW8 decreased the half-
life of MRFAP1 (Figure 4A–4B), whereas knockdown of 
FBXW8 prolonged it (Figure 4C–4D). In summary, these data 
demonstrate that FBXW8 regulates MRFAP1 ubiquitination 
and degradation. 
Cell cycle-dependent degradation of MRFAP1
Because SCF E3 ligase mediates the ubiquitination 
of several proteins in specific phases of the cell cycle, we 
also analyzed the expression of MRFAP1 during the cell 
cycle. Firstly, we created a HeLa cell line stably expressing 
Flag-MRFAP1. These cells were synchronized by double 
thymidine arrest, released, and collected at various time 
points after release. In addition, nocodazole was added to 
the culture after the release from double thymidine arrest 
to activate the spindle checkpoint and prevent exit from 
mitosis. DNA contents of those cells were monitored by 
flow cytometry analysis (FACS), and lysates of these cells 
were tested by immunoblotting. As shown in Figure 5A, 
the protein level of MRFAP1 significantly increased after 
cells entering into mitosis. However, the protein level of 
FBXW8 remained unaltered. Interestingly, the increase 
of MRFAP1 protein level was even early than CyclinB1, 
which is known to be accumulated in early mitosis. In 
order to check how MRFAP1 was regulated when cells 
released from M phase, HeLa cells stably expressing 
Flag-MRFAP1, which were synchronized by nocodazole 
block-and-release, were analyzed by FACS and lysates of 
these cells were tested by immunoblotting (Figure 5B). 
As expected, MRFAP1 was highly accumulated in 
mitosis. However, as cells exited from M phase, MRFAP1 
decreased gradually (Figure 5B). In line with these 
observations, by using immunofluorescence, we found that 
MRFAP1 was accumulated in metaphase, but completely 
disappeared in anaphase and reappeared in telophase 
Figure 1: Proteomics screen identified MRFAP1 as a potential binding partner of Cul7/FBXW8 E3 ligase complex. 
(A) After 4 hours 1 µM MLN4924 treatment, lysates from 293T cells stably expressing either Flag or Flag-FBXW8 were immunoprecipitated 
with anti-FLAG M2 resin. Bound proteins were eluted with FLAG peptide, and all separated cell lysate components were resolved on 10% 
SDS-PAGE gel, stained by Coomassie Brilliant or subjected to immunoblotting with the indicated antibodies. The gel was continuously cut 
and subjected to LC−MS/MS analysis. (B) MRFAP1 was identified as a potential binding partner of FBXW8. Two unique peptides were 
assigned to MRFAP1 from MLN4924 treated Flag-FBXW8 but not FLAG-control 293T cell line. 
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(Figure 5C, top panel). However, silencing the expression 
of FBXW8 prevented the disappearance of MRFAP1 
in anaphase (Figure 5C, bottom panel). Taken together, 
the data validate that MRFAP1 is a novel cell cycle-
regulated protein and cell cycle-dependent degradation of 
MRFAP1was mediated by FBXW8.
Overexpression of MRFAP1 causes mitotic 
aberrations and cell death
Cell cycle is a precisely regulated process and cell 
cycle regulated-proteins usually play crucial roles in 
the regulation processes. Thus, the cell cycle-dependent 
Figure 2: MRFAP1 is associated with FBXW8. (A) HeLa cells were co-transfected with GFP-MRFAP1 (green) and Flag-
FBXW8 (red) vectors for 36 hours, cells were then fixed and stained with anti-Flag antibody. Cell nuclei were stained with DAPI. 
Immunofluorescence was performed with anti-flag antibody followed by Alexa Fluor 594-conjugated anti-mouse IgG antibody (red). Bar 
indicated 20 μm. (B) 293T cells were co-transfected with GFP-MRFAP1 and Flag-FBXW8 vectors for 36 hours, the cell lysates were 
subjected to immunoprecipitation with either GFP or Flag antibodies. Western blot was used to detect the interactions between FBXW8 
and MRFAP1.
Figure 3: FBXW8 regulates MRFAP1 ubiquitination and degradation. (A) 293T cells were transfected with negative control 
or three siRNAs against FBXW8 for 36 hours. The whole cell lysate was subjected to Western blot by the indicated antibodies. (B) 293T 
cells were transfected with increase dose of Flag-FBXW8 plasmids for 36 hours. 10 μM MG132 was added for 6 hours as indicated, and 
the whole cell lysate was subjected to Western blot by the indicated antibodies. (C) 293T cells were transfected with Flag-MRFAP1, 
GFP-FBXW8 or HA-Ubiquitin for 30 hours. After 6 hours MG132 treatment, samples were immunoprecipitated with anti-flag resin, and 
analyzed by immunoblotting with the indicated antibodies.
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degradation of MRFAP1 by FBXW8 during mitosis 
intrigues us to further investigate its biological function 
in cell cycle control. Aberrant expression of cell cycle 
regulated-proteins could lead to genome instability, we 
therefore tested whether MRFAP1 was involved in the 
regulation of genome stability. As depicted in Figure 6A, 
overexpression of MRFAP1 in HeLa cells induced mitotic 
aberrations including binuclear cells, multi-lobed nuclei 
cells and cell death. In contrast, all these defects were hardly 
observed in GFP overexpressed HeLa cells. In agreement, 
HeLa cells with MRFAP1 overexpression exhibited a 
growth retardant phenotype (Figure 6B). Indeed, HeLa 
cells with prolonged MRFAP1 expression showed severe 
cell death by the morphological confirmation, FACS assay 
determination as well as the activation and cleavage of 
caspase-3 (Figure 6C–6F), indicating that failure to degrade 
MRFAP1 in cells produced chromosome instability and 
eventually lead to cell death. 
DISCUSSION
The identification of substrates for ubiquitin E3 
ligases by proteomic assay is extremely difficult, as 
most substrates are rapidly ubiquitylated and degraded 
as a result of their association with E3 ligase. The 
administration of proteasome inhibitors such as MG132 
prevented the degradation of substrates might help to 
improve the identification of substrates of E3 ligases, 
but without sufficient specificity. MLN4924, a potent 
and selective inhibitor of NEDD8-activating enzyme, 
specifically disrupts CRLs-mediated protein turnover 
[12]. Previous studies showed that substrates of CRLs 
were highly accumulated upon MLN4924 administration, 
giving the possibility to identify the substrates of CRLs by 
Mass Spectrum (MS) [13–15]. In this study, we performed 
an immunoprecipitation-based proteomics screen with 
MLN4924 treatment to identify the candidate substrates 
of Cul7/FBXW8 and demonstrated MRFAP1 as a bona 
fide substrate of FBXW8. 
After MRFAP1 has been shown to be one of the 
most up-regulated proteins after NEDD8 inhibition 
in multiple human cell lines [10], we tested whether 
MRFAP1 was regulated by FBXW8. The association 
between MRFAP1 and FBXW8 was confirmed by 
means of immunoprecipitation-Western blot as well as 
exogenous indirect immunostaining. Overexpression of 
Figure 4: FBXW8 regulates the stability of MRFAP1. (A) 293T cells were transfected with empty vector or FBXW8 plasmids for 36 
hours, 10 μM CHX was added for the indicated time. The whole cell lysate were detected by Western blot (A) using the indicated antibodies. 
(B) The intensity of the bands from the experiment shown on A was measured, and the ratio between the relative levels of MRFAP1 and 
β-actin in 0 hour was set as 1.0. (C) 293T cells were transfected with siRNAs targeting FBXW8 or negative control for 36 hours, 10 μM CHX 
was added for the indicated time. The whole cell lysate were detected by Western blot using the indicated antibodies. (n = 3 for each group). 
(D) The intensity of the bands from the experiment shown on C was measured, and the ratio between the relative levels of MRFAP1 and 
β-actin in 0 hour was set as 1.0.
Oncotarget97183www.impactjournals.com/oncotarget
FBXW8 increased the polyubiquitination and decreased 
the stability of MRFAP1, whereas knockdown of FBXW8 
prolonged the half-life of MRFAP1, demonstrating that 
MRFAP1 is the bone fide substrate of Cul7/FBXW8. 
Substrates of F-box proteins usually involved in cell cycle 
control and FBXW8 also played a role in cell proliferation, 
we then examined the expression level of MRFAP1 in cell 
cycle progress. Interestingly, we found MRFAP1 was a 
novel cell cycle-regulated protein that accumulated in 
metaphase, but disappeared thoroughly in anaphase and 
reappeared in telophase. Importantly, this disappearance 
could be abolished by FBXW8-depletion, suggesting that 
FBXW8-mediated MRFAP1 degradation might play a role 
in the progression of normal cell cycle. Indeed, forced 
Figure 5: Cell cycle-dependent degradation of MRFAP1. (A) HeLa cells stably expressing Flag-MRFAP1 was synchronized by 
thymidine for 24 hours. Nocodazole was added to the culture after the release from thymidine arrest. The cells were collected at the indicated 
time and analyzed by FACS. Lysates of these cells were tested by Western blot with the indicated antibodies. (B) HeLa cells stably expressing 
Flag-MRFAP1 was synchronized by thymidine for 12 hours, release for 3 hours, and then blocked by nocodazole for 12 hours. After release 
from the nocodazole block, the cells were collected at the indicated time and analyzed by FACS. Lysates of these cells were tested by 
immunoblotting with the indicated antibodies. (C) HeLa cells stably expressing Flag-MRFAP1 were transfected with siRNAs targeting 
FBXW8 or negative control for 36 hours, fixed with PFA and stained with anti-Flag antibody. Various stage of mitosis cells were shown Int 
(interphase), Pro (prophase), Mid (metaphase), Ana (anaphase), Tel (telophase). Nucleus was stained with DAPI. Bar indicated 10 μm. 
Figure 6: Overexpression of MRFAP1 causes mitotic aberrations and cell death. (A) HeLa cells were transfected with 
pEGFP-N1-MRFAP1 plasmid for 24 hours and fixed with PFA. Nucleus was stained with DAPI. Arrows indicated the binuclear cells 
or multi-lobed nuclei cells.  Bar indicated 10 μm. The percentage of the abnormal mitotic cells was calculated. (n = 3 for each group). 
(B) HeLa cells were transfected with empty vector or pEGFP-N1-MRFAP1 plasmids for 24 hours, cell proliferation were tested by CCK8 
assay. (n = 5 for each group). (C) HeLa cells were transfected with empty vector or pEGFP-N1-MRFAP1 plasmids for 24 hours, subG1 
ratio was analyzed by FACS. (D) HeLa cells were transfected with empty vector or pEGFP-N1-MRFAP1 plasmids for 24 hours, and 
Annexin V positive cells was determined on flow cytometry. (E) HeLa cells were transfected with empty vector or pEGFP-N1-MRFAP1 
plasmids for 24 hours and fixed with PFA. Nucleus was stained with DAPI Arrows indicated the apoptosis cells.  Bar indicated 50μm. The 
percentage of the apoptosis cells was calculated. (n = 3 for each group). (F) HeLa cells were transfected with empty vector or pEGFP-N1-
MRFAP1 plasmids for 24 hours, cells were then lysed and subjected to western blot with cleaved caspase-3 antibody.
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expression of MRFAP1 in HeLa cells caused growth 
retardation and genomic instability, and eventually leading 
to severe mitotic cell death. 
Although F-box proteins tend to recognize specific 
degron sequences within target substrates, prior modifications 
of these degrons are usually required to trigger the interaction 
between F-box proteins and their substrate proteins, such 
as phosphorylation, glycosylation and acetylation [4, 16]. 
To this end, we have also purified MRFAP1 protein and 
determined the potential phosphorylation sites of it by MS. 
However, we could not identify any phosphorylation sites 
(data not shown) and MRFAP1 itself has not been reported to 
be phosphorylated even in public phosphorylation database, 
suggesting phosphorylation might not be required for the 
interaction between MRFAP1 and FBXW8. Nevertheless, 
further studies are required to clarify the interacting details 
between MRFAP1 and FBXW8. 
Although we have confirmed that MRFAP1 
overexpression resulted in decreased cell growth and increased 
mitotic apoptosis, whether MRFAP1 contributes to DNA re-
replication, DNA damage signaling, senescence or autophagy 
(a phenomena could be observed after MLN4924 treatment) 
remained completely unknown [17]. Thus, our data has set 
up the stage for the MRFAP1 function, physiological and 
pathophysiological significances related researches.
In summary, in this manuscript, by using an 
immunoprecipitation-based proteomics screen, we 
identified MRFAP1 was a novel cell cycle-regulated protein 
and Cul7/FBXW8-mediated destruction of MRFAP1 could 
be a regulatory component monitoring the anaphase-
telophase transition and preventing genomic instability.  
MATERIALS AND METHODS
Cell culture and treatments
293T and HeLa cells were purchased from the 
American Type Culture Collection (ATCC). All cells 
were cultured in Dulbecco’s modified Eagle’s medium 
supplemented with 10% fetal bovine serum in a 5% 
CO
2
/95% air at 37°C under saturated humidity. Dulbecco’s 
modified Eagle’s medium, fetal bovine serum and trypsin 
were obtained from Invitrogen (U.S.A). MLN4924 (HY-
10484, NEDD8-Cullin E3 ligase pathway inhibitor) was 
purchased from Med Chem Express (U.S.A). Puromycin 
(P9620, selective agent in eukaryotic cell culture systems), 
Thymidine (T1895, DNA synthesis inhibitor), MG132 
(M8699, proteasome inhibitor), nocodazole (M1404, mitotic 
spindle inhibitor), cycloheximide (C1988, eukaryote protein 
synthesis inhibitor) and FLAG M2 Affinity Gel (A2220) 
were obtained from Sigma (U.S.A). 
Constructs and vectors
MRFAP1 (gene accession number: NM_001272053.1) 
and FBXW8 (gene accession number: NM_012174.1) 
constructs were generated by gene synthesis and cloned into 
the pEGFP-N1, pCDNA3.1(-), and pBABE-3XFlag vector. 
The construction of retrovirus based stable expression cell 
lines has been described previously [18]. 
CCK8 assay
HeLa cells were inoculated in a 96-well plate 24 hours 
before transfection. CCK8 (cell counting kit C0038, 
Beyotime Biotechnology, China) solution was added to each 
well of the plate 24 hours after transfection. The plate was 
then incubated for 4 hours in an incubator. The absorbance 
at 450 nm was measured by using a microplate reader 
(SpectraMax Paradigm, Molecular Devices, USA).
siRNAs
FBXW8-specific siRNAs were purchased from 
RiboBio (Guangzhou, China). The siRNA sequences 
for human FBXW8 were: No1 5′ GGAGCAUGUUC 
CUGACACA 3′, No2 5′ GAAGCAAGAUCCUGGUGUA 3′, 
No3 5′ CAGGAAAGAACUAGGAAGA 3′. 293T-MRFAP1 
cell line was plated in a 24-well tissue culture plate for 
20 to 24 hours before transfection. For transfection of 
siRNAs, cells were transfected with 100 nM of siRNA 
using 1 μL Lipofectamine® 2000 for each well. Cells were 
then harvested 48 hours after transfection.  
Protein purification, in-gel digestion and  
Nano-LC−ESI−MS/MS analysis
The whole IP/MS analysis procedure has been 
described previously [19]. 
Immunofluorescence microscopy 
Cells were cultured on glass coverslips as described 
above and then fixed with 4% paraformaldehyde in 
PBS. Fixed cells were washed with PBS and then 
permeabilized using 1 % Triton X-100 for 10 min 
followed by washing with PBS. Coverslips were 
processed for immunolabeling by blocking with 5% 
BSA in TBST. Cells were incubated with primary 
antibodies in 5% BSA in TBST on coverslips for 1 hour. 
The coverslips were washed with PBS for three times. 
Primary antibodies were detected with Alexa Fluor 488 
or Alexa Fluor 594-conjugated secondary antibodies 
by incubating on coverslips for 30 min in 5% BSA in 
TBST. Paraformaldehyde, Triton X-100, and BSA were 
obtained from sinopharm chemical reagent co.,Ltd 
(China). Alexa Fluor 488 or Alexa Fluor 594-conjugated 
secondary antibodies were obtained from Invitrogen 
(U.S.A). Anti-FLAG antibody (1:1000 dilution, F1804) 
was purchased from Sigma, U.S.A, Polyclonal anti-
MRFAP1 (1:500 dilution, 11639-1-AP) was purchased 
from Ptglab, Wuhan, Hubei, China, Polyclonal anti-
FBXW8 (1:500 dilution, sc-167864) was obtained from 
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Santa cruz, U.S.A. Images were captured by fluorescence 
microscopy (Bx53, Olympus, Japan).
Western blot
Cells were harvested and lysed with ice-cold 
lysis buffer (62.5 mM Tris-HCl, pH 6.8, 100 mM 
DTT, 2% SDS, 10 % glycerol). After centrifugation at 
12,000 g for 10 min at 4°C, proteins in the supernatants 
were quantified and separated by 10 or 12 % SDS-
PAGE, either stained by Coomassie Brilliant Blue or 
transferred to NC membrane (Amersham Bioscience, 
Buckinghamshire, U.K.). Primary antibodies used as 
indicated: monoclonal anti-Flag M2 (F1804, Sigma, 
U.S.A), monoclonal anti-Flag M2-Peroxidase (HRP) 
antibody (1:5000 dilution, A8592, Sigma, U.S.A), 
Polyclonal anti-MRFAP1 (1:2000 dilution, 11639-1-
AP, Ptglab, Wuhan, Hubei, China), Polyclonal anti-
FBXW8 (1:1000 dilution, sc-167864, Santa cruz, U.S.A). 
Polyclonal anti-Cyclin B1 (1:2000 dilution, 55004-1-
Ap, Ptglab, Wuhan, Hubei, China) or  polyclonal anti-
Cyclin B1(1:1000 dilution, sc-4073, Santa cruz, U.S.A), 
polyclonal anti-GAPDH (1:5000 dilution, 60004-1-Ig, 
Ptglab, Wuhan, Hubei, China)  
Cell cycle synchronization
For nocodazole-thymidine cell cycle 
synchronization, HeLa cells stably expressing Flag-
MRFAP1 were inoculated into a 6-well plate, and 
treated with 2 mM thymidine for 24 hours, then washed 
with PBS for 3 times. 0.3 mM nocodazole was added to 
the culture and the cells were collected at the indicated 
time for FACS or Western blot analysis. For nocodazole 
release cell cycle synchronization, HeLa cells stably 
expressing Flag-MRFAP1 were inoculated into the 
6-well plate, and treated with 2 mM thymidine for 12 
hours, then washed with PBS for 3 times. After 3 hours, 
cells were treated with 0.3 mM nocodazole for 12 
hours, then washed with PBS for 3 times. After release 
from the nocodazole block, the cells were collected at 
the indicated time for FACS or Western blot analysis.
FACS assay
The whole FACS analysis procedure has been 
described previously [20]. 
Statistical analysis
The Statistical Package for the Social Sciences 
software version 15.0.1 (SSPS 15.0.1.) was used for 
statistical analysis. Values were shown as mean ± SEM. 
Statistical differences were determined by a Student t test. 
Statistical significance is displayed as *p < 0.05, **p < 0.01 
or ***p < 0.001.
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